E-viri
Recenzirano
Odprti dostop
-
Dienstag, Jules L; Schiff, Eugene R; Wright, Teresa L; Perrillo, Robert P; Hann, Hie-Won L; Goodman, Zachary; Crowther, Lynn; Condreay, Lynn D; Woessner, Mary; Rubin, Marc; Brown, Nathaniel A
New England journal of medicine/The New England journal of medicine, 10/1999, Letnik: 341, Številka: 17Journal Article
Hepatitis B virus (HBV) infects more than 300 million people worldwide, contributing to debilitating illness and death. 1 Until recently, the only antiviral drug for the treatment of hepatitis B was interferon. 2 – 4 In preliminary studies of patients with chronic hepatitis B, lamivudine, an oral nucleoside analogue, 5 was well tolerated and suppressed serum levels of HBV DNA profoundly. 6 – 9 We therefore conducted a one-year study of the efficacy of lamivudine in patients with chronic hepatitis B. After our data on patients had been collected, Lai et al. 10 reported the results of a placebo-controlled study in which they found histologic, biochemical, and . . .
